Guru Sonpavde: Cabozantinib Plus PD1 Inhibition Immunotherapy Active
Guru Sonpavde, GU Oncology and Phase I Clinical Trials Director, Chair of Bladder Cancer Research at AdventHealth Central Florida, shared on LinkedIn about a recent paper by Rohit K. Jain et al. published in ScienceDirect:
“Bladder Cancer- Angiogenesis (VEGF) inhibition (cabozantinib) plus PD1 inhibition immunotherapy (pembrolizumab) active (response rate 46%) as firstline therapy for cisplatin-ineligible advanced urothelial carcinoma-median PFS and OS of 8 and 17 months in 35 evaluable patients- European Urology Oncology – Do VEGF inhibitors deserve further evaluation perhaps using novel potent agents?
The absence of neurotoxicity is a plus in patients following Enfortumab Vedotin (EV) plus pembrolizumab- pleased to collaborate from AdventHealth Central Florida cancer Institute with Neeraj Agarwal.”
Title: Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma: The PemCab Trial
Authors: Rohit K. Jain, Umang Swami, Mehmet A. Bilen, Georges Gebrael, Kenneth M. Boucher, Emma Braun, Jacqueline T. Brown, Jad Chahoud, Sumati Gupta, Neeraj Agarwal, Guru Sonpavde, Benjamin L. Maughan
See insightful article about Bladder Cancer on OncoDaily:
“FDA Approves Durvalumab for Muscle Invasive Bladder Cancer”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023